AHPA Comments On Vinpocetine: Health And Wellness Industry News Roundup
This article was originally published in The Rose Sheet
AHPA argues FDA erred in vinpocetine proposal; and MusclePharm CEO bails out firm again.
You may also be interested in...
Mannatech slumps on Americas downturn; MusclePharm navigates bumps in turnaround; kratom recalls updated; and FDA, DoJ shutter another supplement firm
Viehbacher’s investment group backs start-up supplement firm; Former Starbucks executive joins Jamba Juice as COO; and MusclePharm forecasts turning corner in 2017.
NPA CEO Daniel Fabricant says some vinpocetine product marketers don't realize the ingredient's status as an active moiety of a botanical long used in the food supply, a knowledge gap obscures that FDA is using an extra-regulatory procedure to remove vinpocetine.